Defining the Intensity of Conditioning Regimens: Working Definitions

Overview

Journal Biol Blood Marrow Transplant

Date 2009 Nov 10

PMID 19896087

Citations 655

Authors

Andrea Bacigalupo

Karen Ballen

Doug Rizzo

Sergio Giralt

Hillard Lazarus

Vincent Ho

Jane Apperley

Shimon Slavin

Marcelo Pasquini

Brenda M Sandmaier

John Barrett

Didier Blaise

Robert Lowski

Mary Horowitz

Affiliations

Soon will be listed here.

Abstract

Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant (HSCT) community. In the present report we propose to define conditioning regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity conditioning (RIC), and (3) nonmyeloablative (NMA) conditioning. Assignment to these categories is based on the duration of cytopenia and on the requirement for stem cell (SC) support: MA regimens cause irreversible cytopenia and SC support is mandatory. NMA regimens cause minimal cytopenia, and can be given also without SC support. RIC regimens do not fit criteria for MA or NMA regimens: they cause cytopenia of variable duration, and should be given with stem cell support, although cytopenia may not be irreversible. This report also assigns commonly used regimens to one of these categories, based upon the agents, dose, or combinations. Standardized classification of conditioning regimen intensities will allow comparison across studies and interpretation of study results.

Citing Articles

Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT.

Stuut A, Nijssen C, van der Wagen L, van Rhenen A, Daenen L, Janssen A Bone Marrow Transplant. 2025; .

PMID: 40089614 DOI: 10.1038/s41409-025-02538-w.

Effect of conditioning intensity on late complications in AYA who underwent allogeneic HCT during childhood.

Shimomura M, Ashiarai M, Kato I, Kamiya T, Taketomi N, Akita T Int J Hematol. 2025; .

PMID: 40063330 DOI: 10.1007/s12185-025-03961-x.

Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation.

Masuda Y, Honda A, Oyama T, Masamoto Y, Kurokawa M Int J Hematol. 2025; .

PMID: 40032737 DOI: 10.1007/s12185-025-03949-7.

Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.

Masuda Y, Sadato D, Toya T, Hosoda Y, Hirama C, Shimizu H Int J Hematol. 2025; .

PMID: 40011351 DOI: 10.1007/s12185-025-03951-z.

cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies.

Rowley S, Albitar M, Baker M, Ali A, Kaur S, Suh H Cancers (Basel). 2025; 17(4).

PMID: 40002220 PMC: 11853444. DOI: 10.3390/cancers17040625.

References

BROWN R, Herzig R, Wolff S, Frei-Lahr D, Pineiro L, Bolwell B . High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood. 1990; 76(3):473-9. View

Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A . Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant. 2002; 30(12):813-31. DOI: 10.1038/sj.bmt.1703819. View

Hegenbart U, Niederwieser D, Sandmaier B, Maris M, Shizuru J, Greinix H . Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2005; 24(3):444-53. DOI: 10.1200/JCO.2005.03.1765. View

Kanfer E, Buckner C, Fefer A, Storb R, Appelbaum F, Hill R . Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation. Bone Marrow Transplant. 1987; 1(4):339-46. View

Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J . Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006; 108(3):836-46. DOI: 10.1182/blood-2005-11-4503. View

Jamieson C, Amylon M, Wong R, Blume K . Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. Exp Hematol. 2003; 31(10):981-6. DOI: 10.1016/s0301-472x(03)00231-5. View

Robinson S, Goldstone A, Mackinnon S, Carella A, Russell N, de Elvira C . Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002; 100(13):4310-6. DOI: 10.1182/blood-2001-11-0107. View

Terenzi A, Aristei C, Aversa F, Perruccio K, Chionne F, Raymondi C . Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc. 1996; 28(6):3101. View

Sorror M, Maris M, Storer B, Sandmaier B, Diaconescu R, Flowers C . Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004; 104(4):961-8. DOI: 10.1182/blood-2004-02-0545. View

10.

Storb R . Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia?. Leukemia. 2001; 15(4):662-3. DOI: 10.1038/sj.leu.2402034. View

11.

Tutschka P, Copelan E, Klein J . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987; 70(5):1382-8. View

12.

Ballen K, Colvin G, Porter D, Quesenberry P . Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review. Leuk Lymphoma. 2004; 45(5):905-10. PMC: 1986764. DOI: 10.1080/10428190310001628167. View

13.

Marks D, Forman S, Blume K, Perez W, Weisdorf D, Keating A . A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006; 12(4):438-53. DOI: 10.1016/j.bbmt.2005.12.029. View

14.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, CIVIDALLI G . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3):756-63. View

15.

Maloney D, Molina A, Sahebi F, Stockerl-Goldstein K, Sandmaier B, Bensinger W . Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003; 102(9):3447-54. DOI: 10.1182/blood-2002-09-2955. View

16.

Childs R, Clave E, Tisdale J, Plante M, Hensel N, Barrett J . Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol. 1999; 17(7):2044-9. DOI: 10.1200/JCO.1999.17.7.2044. View

17.

Pagel J, Matthews D, Appelbaum F, Bernstein I, Press O . The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant. 2002; 29(10):807-16. DOI: 10.1038/sj.bmt.1703524. View

18.

Bacigalupo A . Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant. 2004; 33(7):691-6. DOI: 10.1038/sj.bmt.1704416. View

19.

Lucarelli G, Polchi P, Izzi T, Manna M, DELFINI C, Galimberti M . Marrow transplantation for thalassemia after treatment with busulfan and cyclophosphamide. Ann N Y Acad Sci. 1985; 445:428-31. DOI: 10.1111/j.1749-6632.1985.tb17212.x. View

20.

Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P . Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol. 2005; 23(27):6690-8. DOI: 10.1200/JCO.2005.07.070. View